HP’s Dividend Helps, but Cash Returns Cannot Fix Slow Growth

HP generated $1.6 billion of free cash flow in its fiscal third quarter and returned nearly $600 million. Dividends add meaningful income, but five-year total-return data show they have not closed the gap with the broader market.
HP continues to produce enough cash from PCs and printers to reward shareholders, but the dividend has not erased the cost of owning a slow-growth business.
In its fiscal third quarter of 2026, HP generated $1.6 billion of free cash flow and returned nearly $600 million through dividends and share repurchases. Management has said it intends to return approximately all free cash flow to shareholders over time, subject to keeping gross leverage below two times.
That policy is tangible. A five-year comparison published by Trefis found that HP shares gained 6.4% on price alone through October 12, 2026, while reinvested dividends lifted the total return to 28.4%. Dividends therefore supplied most of the shareholder gain.
The relevant benchmark also pays dividends. Over the same period, the S&P 500 returned 81.5% on price and 93.6% with dividends reinvested, measured through the SPDR S&P 500 ETF. HP’s income narrowed the total-return deficit by 10 percentage points, but the stock still trailed by 65.2 percentage points.
The comparison illustrates what a dividend can and cannot do. It distributes cash already generated by the business, which is valuable to income investors, but it does not create growth. HP still depends heavily on mature PC and printing markets. Those segments can generate substantial cash while offering less reinvestment upside than faster-growing parts of the technology sector.
Buybacks add another layer. Repurchases create value when the company buys shares below intrinsic value and the remaining business can sustain its cash flows. They are less helpful if declining earnings offset the lower share count. Investors therefore need to watch unit demand, margins and free cash flow rather than treating the payout alone as protection.
HP’s capital-return policy may suit an investor who prioritizes current income and accepts slower growth. It is not a substitute for business improvement. The company must preserve cash generation through product cycles and cost pressure if the dividend and repurchase program are to remain durable.
The next reports should be judged on free cash flow, leverage and the performance of Personal Systems and Printing. A high payout ratio can reward owners, but only operating results can close the long-term return gap.
Continue your SPY research
Related News
NYSE Extends Options Trading, but Early Volume Shows the Limits
NYSE added premarket and post-close options sessions for 29 heavily traded stocks and funds. The launch answers demand for longer trading access, but thin initial volume highlights liquidity and execution risks.
Trump Media and Rumble Fell Faster Than the Market as Merger Risk Loomed
Trump Media dropped 6% and Rumble 8% during a broader selloff, highlighting their high volatility. For DJT, the pending TAE merger adds execution, dilution and fusion-development risk.
Carnival's Record 2027 Bookings Shift Attention to Pricing
Carnival reported record booked occupancy and pricing for 2027, supporting demand visibility after a strong share-price rebound. The next test is whether realized yields and costs preserve that advantage.
CoreWeave Credit Insurance Tops 1,000 Basis Points as Debt Fears Rise
CoreWeave's five-year credit-default swaps moved above 1,000 basis points while a 2031 bond yielded about 14.5%. Those market prices signal severe perceived credit risk even though the company continues to add long-term customer commitments.
Reddit's 61% Growth Supports Its Premium, but the Next Quarter Slows
Reddit's second-quarter revenue rose 61% and weekly active uniques reached 514.6 million, supporting a richer valuation than slower-growing peers. Management's third-quarter guide, however, implies a clear deceleration and leaves search traffic as a risk.
Disc Medicine's Phase 3 Win Clears the Clinical Bar, Not the FDA Bar
Bitopertin met both primary endpoints in Disc Medicine's pivotal APOLLO trial, strengthening its planned response to an earlier FDA rejection. The next value-driving step is regulatory acceptance, not another share-price reaction.










Latest comments